Biology and therapy of multiple myeloma

被引：120

作者：

Joshua, Douglas E. ^{[1
]}

Bryant, Christian ^{[1
]}

Dix, Caroline ^{[1
]}

Gibson, John ^{[1
]}

Ho, Joy ^{[1
]}

机构：

[1] Royal Prince Alfred Hosp, Sydney, NSW, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2019年 / 210卷 / 08期

关键词：

Myeloma; Immunotherapies; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; MONOCLONAL GAMMOPATHY; POSITION STATEMENT; SUBGROUP ANALYSIS; OPEN-LABEL; LONG-TERM; DEXAMETHASONE; SURVIVAL; LENALIDOMIDE;

D O I：

10.5694/mja2.50129

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Genetic sequencing of the myeloma genome has not revealed a specific disease-determining genetic alteration. Multiple disease subclones exist at diagnosis and vary in clinical importance with time and drug sensitivity. New diagnostic criteria have identified indications for early introduction of therapy. Autologous stem cell transplantation remains an essential component of therapy in young and fit patients. The use of continual suppressive (maintenance) therapy has been established as an important component in therapy. Immune therapies and the harnessing of the innate immune system offer great promise for future treatments. Since 2005, quality of life, supportive therapies, and survival have dramatically improved over a decade of remarkable progress. The common manifestations of multiple myeloma, such as bone pain, fatigue and weight loss, may be non-specific and are often initially ignored or missed by patients and medical practitioners.

引用

页码：375 / 380

页数：6

共 67 条

[1] Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial [J].

Ailawadhi, S. ;

Mikhael, J. R. ;

LaPlant, B. R. ;

Laumann, K. M. ;

Kumar, S. ;

Roy, V. ;

Dingli, D. ;

Bergsagel, P. L. ;

Buadi, F. K. ;

Rajkumar, S. V. ;

Fonseca, R. ;

Gertz, M. A. ;

Kapoor, P. ;

Sher, T. ;

Hayman, S. R. ;

Stewart, A. K. ;

Dispenzieri, A. ;

Kyle, R. A. ;

Gonsalves, W. I. ;

Reeder, C. B. ;

Lin, Y. ;

Go, R. S. ;

Leung, N. ;

Kourelis, T. ;

Lust, J. A. ;

Russell, S. J. ;

Chanan-Khan, A. A. ;

Lacy, M. Q. .

LEUKEMIA, 2018, 32 (03) :719-728

[2]

Australian Institute of Health and Welfare, 2017, AUSTR I HLTH WELF CA, V101

[3] Darwinian evolution and tiding clones in multiple myeloma [J].

Bahlis, Nizar J. .

BLOOD, 2012, 120 (05) :927-928

[4] Checkpoint inhibition in myeloma [J].

Benson, Don M., Jr. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :528-533

[5] Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry [J].

Bergin, Krystal ;

Moore, Elizabeth ;

McQuilten, Zoe ;

Wood, Erica ;

Augustson, Bradley ;

Blacklock, Hilary ;

Ho, Joy ;

Horvath, Noemi ;

King, Tracy ;

McNeil, John ;

Mollee, Peter ;

Quach, Hang ;

Reid, Christopher M. ;

Rosengarten, Brian ;

Walker, Patricia ;

Spencer, Andrew .

BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16 :1-8

[6] Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry [J].

Blimark, Cecilie Hveding ;

Turesson, Ingemar ;

Genell, Anna ;

Ahlberg, Lucia ;

Bjorkstrand, Bo ;

Carlson, Kristina ;

Forsberg, Karin ;

Juliusson, Gunnar ;

Linder, Olle ;

Mellqvist, Ulf-Henrik ;

Nahi, Hareth ;

Kristinsson, Sigurdur Y. .

HAEMATOLOGICA, 2018, 103 (03) :506-513

[7] Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups [J].

Bolli, Niccolo ;

Biancon, Giulia ;

Moarii, Matahi ;

Gimondi, Silvia ;

Li, Yilong ;

de Philippis, Chiara ;

Maura, Francesco ;

Sathiaseelan, Vijitha ;

Tai, Yu-Tzu ;

Mudie, Laura ;

O'Meara, Sarah ;

Raine, Keiran ;

Teague, Jon W. ;

Butler, Adam P. ;

Carniti, Cristiana ;

Gerstung, Moritz ;

Bagratuni, Tina ;

Kastritis, Efstathios ;

Dimopoulos, Meletios ;

Corradini, Paolo ;

Anderson, Kenneth C. ;

Moreau, Philippe ;

Minvielle, Stephane ;

Campbell, Peter J. ;

Papaemmanuil, Elli ;

Avet-Loiseau, Herve ;

Munshi, Nikhil C. .

LEUKEMIA, 2018, 32 (12) :2604-2616

[8] Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy A Randomized Clinical Trial [J].

Bridoux, Frank ;

Carron, Pierre-Louis ;

Pegourie, Brigitte ;

Alamartine, Eric ;

Augeul-Meunier, Karine ;

Karras, Alexandre ;

Joly, Bertrand ;

Peraldi, Marie-Noelle ;

Arnulf, Bertrand ;

Vigneau, Cecile ;

Lamy, Thierry ;

Wynckel, Alain ;

Kolb, Brigitte ;

Royer, Bruno ;

Rabot, Nolwenn ;

Benboubker, Lotfi ;

Combe, Christian ;

Jaccard, Arnaud ;

Moulin, Bruno ;

Knebelmann, Bertrand ;

Chevret, Sylvie ;

Fermand, Jean-Paul .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (21) :2099-2110

[9] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study [J].

Bringhen, Sara ;

Mina, Roberto ;

Cafro, Anna Maria ;

Liberati, Anna Marina ;

Spada, Stefano ;

Belotti, Angelo ;

Gaidano, Gianluca ;

Patriarca, Francesca ;

Troia, Rossella ;

Fanin, Renato ;

De Paoli, Lorenzo ;

Rossi, Giuseppe ;

Lombardo, Alessandra ;

Bertazzoni, Paola ;

Palumbo, Antonio ;

Sonneveld, Pieter ;

Boccadoro, Mario .

LEUKEMIA, 2018, 32 (08) :1803-1807

[10]

Bu De-Xiu, 2018, Oncotarget, V9, P25764, DOI 10.18632/oncotarget.25359

← 1 2 3 4 5 6 7 →